Schacht Research Study 19-2335
Primary Objective
Evaluate the effects of a medication, tolcapone (TOLC), on non-treatment-seeking individuals with Alcohol Use Disorder and Attention-Deficit/Hyperactivity Disorder (ADHD).
Description
This study evaluates the effects of an FDA-approved medication called tolcapone in people who have both Alcohol Use Disorder (AUD) and Attention-Deficit/Hyperactivity Disorder (ADHD). The study involves seven visits over a three to four week period, including an assessment visit and two eight-day medication periods during which participants will be assigned to take, in a double-blinded fashion, both tolcapone and a placebo (three visits during each period). During the study period there will be two fMRI scans and two on-campus alcohol administration sessions. Participants must not be seeking treatment for AUD or ADHD and must not be currently taking any psychotropic medications, including stimulant medications for ADHD.
Details
Locations
Brain Imaging Center (BIC)
Department Specific Free Standing Clinic
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Joseph Schacht
Study ID
Protocol Number: 19-2335
More information available at ClinicalTrials.gov: NCT03904498
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers